CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net income		$ 82,464	$ 51,810	$ 144,641	$ 132,004
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation				126,981	115,755
Amortization of intangible and other assets and favorable/unfavorable leases				1,704	738
Amortization of long-term prepaid rents		597	496	1,236	989
Amortization of debt issue costs				2,913	3,063
Loss on debt amendments			246	1,484	246
Amortization of deferred revenues, deferred lease incentives and other				(10,762)	(7,923)
Impairment of long-lived assets		2,788	4,301	3,379	4,574
Share based awards compensation expense		3,452	3,203	6,878	6,444
Loss on disposal of assets and other		16,901	54	20,840	888
Deferred lease expenses		(449)	(375)	(932)	(722)
Equity in income of affiliates		(6,414)	(5,805)	(15,050)	(15,865)
Deferred income tax expenses				7,669	14,515
Distributions from equity investees	[1]	3,932	2,870	16,255	14,919
Changes in assets and liabilities and other				(27,333)	(33,935)
Net cash provided by operating activities				279,903	235,690
Investing activities
Additions to theatre properties and equipment		(82,426)	(91,613)	(162,589)	(182,800)
Acquisitions of theatres in the U.S. and international markets, net of cash acquired				(11,508)	(40,829)
Proceeds from sale of theatre properties and equipment and other				2,135	14,521
Investment in joint ventures and other, net				(19,467)	(466)
Net cash used for investing activities				(191,429)	(209,574)
Financing activities
Dividends paid to stockholders				(74,723)	(67,528)
Payroll taxes paid as a result of stock withholdings				(2,905)	(2,921)
Repayments of long-term debt				(3,298)	(1,427)
Payment of debt issue costs				(5,103)	(521)
Fees paid related to debt amendments				(704)	(246)
Payments on capital leases				(12,377)	(10,143)
Other					(311)
Net cash used for financing activities				(99,110)	(83,097)
Effect of exchange rate changes on cash and cash equivalents				(7,199)	(75)
Decrease in cash and cash equivalents				(17,835)	(57,056)
Cash and cash equivalents:
Beginning of period				522,547	561,235
End of period		$ 504,712	$ 504,179	$ 504,712	$ 504,179

[1] Includes cash distributions received from equity investees that were recorded as a reduction of the respective investment balances (see Notes 7 and 8). These distributions are reported entirely within the U.S. operating segment.